Cargando…
Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA
Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease in which synovial fibroblasts (SF) play a key role. Baricitinib and Tofacitinib both act intracellularly, blocking the ATP-binding side of JAK proteins and thereby the downstream signalling pathway via STAT-3. Therefore, we inves...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556031/ https://www.ncbi.nlm.nih.gov/pubmed/32927842 http://dx.doi.org/10.3390/ijms21186632 |
_version_ | 1783594145910095872 |
---|---|
author | Amrhein, Jan Drynda, Susanne Schlatt, Lukas Karst, Uwe Lohmann, Christoph H. Ciarimboli, Giuliano Bertrand, Jessica |
author_facet | Amrhein, Jan Drynda, Susanne Schlatt, Lukas Karst, Uwe Lohmann, Christoph H. Ciarimboli, Giuliano Bertrand, Jessica |
author_sort | Amrhein, Jan |
collection | PubMed |
description | Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease in which synovial fibroblasts (SF) play a key role. Baricitinib and Tofacitinib both act intracellularly, blocking the ATP-binding side of JAK proteins and thereby the downstream signalling pathway via STAT-3. Therefore, we investigated the role of organic cation transporters (OCTs) in Baricitinib and Tofacitinib cellular transport. Methods: OCT expression was analysed in SF isolated from RA and osteoarthritis (OA) patients, as well as peripheral blood mononuclear cells. The interaction of Baricitinib and Tofacitinib with OCTs was investigated using quenching experiments. The intracellular accumulation of both drugs was quantified using LC/MS. Target inhibition for both drugs was tested using Western blot for phosphorylated JAK1 and STAT3 upon stimulation with IL-6. Results: MATE-1 expression increased in OASF compared to RASF. The other OCTs were not differentially expressed. The transport of Baricitinib was not OCT dependent. Tofacitinib; however, was exported from RASF in a MATE-1 dependent way. Tofacitinib and Baricitinib showed comparable inhibition of downstream signalling pathways. Conclusion: We observed different cellular uptake strategies for Baricitinib and Tofacitinib. Tofacitinib was exported out of healthy cells due to the increased expression of MATE1. This might make Tofacitinib the favourable drug. |
format | Online Article Text |
id | pubmed-7556031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75560312020-10-19 Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA Amrhein, Jan Drynda, Susanne Schlatt, Lukas Karst, Uwe Lohmann, Christoph H. Ciarimboli, Giuliano Bertrand, Jessica Int J Mol Sci Article Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease in which synovial fibroblasts (SF) play a key role. Baricitinib and Tofacitinib both act intracellularly, blocking the ATP-binding side of JAK proteins and thereby the downstream signalling pathway via STAT-3. Therefore, we investigated the role of organic cation transporters (OCTs) in Baricitinib and Tofacitinib cellular transport. Methods: OCT expression was analysed in SF isolated from RA and osteoarthritis (OA) patients, as well as peripheral blood mononuclear cells. The interaction of Baricitinib and Tofacitinib with OCTs was investigated using quenching experiments. The intracellular accumulation of both drugs was quantified using LC/MS. Target inhibition for both drugs was tested using Western blot for phosphorylated JAK1 and STAT3 upon stimulation with IL-6. Results: MATE-1 expression increased in OASF compared to RASF. The other OCTs were not differentially expressed. The transport of Baricitinib was not OCT dependent. Tofacitinib; however, was exported from RASF in a MATE-1 dependent way. Tofacitinib and Baricitinib showed comparable inhibition of downstream signalling pathways. Conclusion: We observed different cellular uptake strategies for Baricitinib and Tofacitinib. Tofacitinib was exported out of healthy cells due to the increased expression of MATE1. This might make Tofacitinib the favourable drug. MDPI 2020-09-10 /pmc/articles/PMC7556031/ /pubmed/32927842 http://dx.doi.org/10.3390/ijms21186632 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Amrhein, Jan Drynda, Susanne Schlatt, Lukas Karst, Uwe Lohmann, Christoph H. Ciarimboli, Giuliano Bertrand, Jessica Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA |
title | Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA |
title_full | Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA |
title_fullStr | Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA |
title_full_unstemmed | Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA |
title_short | Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA |
title_sort | tofacitinib and baricitinib are taken up by different uptake mechanisms determining the efficacy of both drugs in ra |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556031/ https://www.ncbi.nlm.nih.gov/pubmed/32927842 http://dx.doi.org/10.3390/ijms21186632 |
work_keys_str_mv | AT amrheinjan tofacitinibandbaricitinibaretakenupbydifferentuptakemechanismsdeterminingtheefficacyofbothdrugsinra AT dryndasusanne tofacitinibandbaricitinibaretakenupbydifferentuptakemechanismsdeterminingtheefficacyofbothdrugsinra AT schlattlukas tofacitinibandbaricitinibaretakenupbydifferentuptakemechanismsdeterminingtheefficacyofbothdrugsinra AT karstuwe tofacitinibandbaricitinibaretakenupbydifferentuptakemechanismsdeterminingtheefficacyofbothdrugsinra AT lohmannchristophh tofacitinibandbaricitinibaretakenupbydifferentuptakemechanismsdeterminingtheefficacyofbothdrugsinra AT ciarimboligiuliano tofacitinibandbaricitinibaretakenupbydifferentuptakemechanismsdeterminingtheefficacyofbothdrugsinra AT bertrandjessica tofacitinibandbaricitinibaretakenupbydifferentuptakemechanismsdeterminingtheefficacyofbothdrugsinra |